Acute Kidney Injury
Conditions
Brief summary
A Phase 1b study to evaluate the safety, tolerability and pharmacodynamic effect of RBT-1 in healthy volunteers and subjects with stage 3b-4 CKD.
Detailed description
This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with stage 3b-4 CKD. The following biomarkers will be used as surrogate measures of protective activity: Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL-10, and Heme Oxygenase-1. Additionally, the P21 biomarker will be monitored at various points of the study.
Interventions
DRUGFeS and SnPP
Escalating doses of drug will be compared for biomarker changes
Sponsors
Renibus Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male and female subjects age 18 to 80 years (inclusive, at time of ICF). 2. Body weight \<125 kg. 3. Able and willing to comply with all study procedures. 4. Female subjects must be either post-menopausal for at least 1 year or surgically sterile (tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until 28 days after study drug administration. Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 28 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation. 5. CKD as determined by estimated glomerular filtration rate (GFR) between 15-45 ml/min as estimated using the CKD-EPI equation (CKD class 3b-4). -
Exclusion criteria
1. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non-melanoma skin cancers. 2. Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to screening, whichever is longer. 3. Serum ferritin \> 500 ng/ml or who have received IV iron within 28 days of screening, or currently being treated with oral iron. 4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study. 5. Regular use of drugs of abuse and/or positive findings on urinary drug screening. 6. Current tobacco use and/or positive findings on urinary cotinine screening. 7. Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol. 8. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated. 9. Known hypersensitivity or previous anaphylaxis to RBT-1 or to components thereof. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of RBT-1 on biomarkers of cytoprotective activity | 7 days | Measuring Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL-10, and Heme Oxygenase-1, the P21 biomarker systemic levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 7 days | Safety and tolerability of RBT-1 in Healthy Volunteers and subjects with CKD |
| Establish the optimal dose for future development | 60 days | The highest dose of RBT-1 with the best safety and tolerability will be determined |
Outcome results
None listed